21 active not recruiting. 21 Phase 3.
By phase and status
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Trials (filtered) newest first · largest first
All 21 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Zasocitinib, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | 601 | 2025-03-10 | 2026-10-14 |
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Icotrokinra, Placebo, Active reference comparator - Arthritis, Psoriatic | Phase 3 | Active not recruiting | 552 | 2025-02-21 | 2026-11-03 |
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
Icotrokinra, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | 813 | 2025-01-09 | 2026-11-03 |
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo - Plaque Psoriasis, Psoriasis (PsO) | Phase 3 | Active not recruiting | 1680 | 2025-01-08 | 2026-04-13 |
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
SHR-1314 injection, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | 208 | 2024-11-04 | 2026-08-06 |
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Sonelokimab, Placebo, Risankizumab - Arthritis, Psoriatic | Phase 3 | Active not recruiting | 600 | 2024-10-15 | 2026-10-09 |
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
Sonelokimab, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | 960 | 2024-10-15 | 2026-10-09 |
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Active not recruiting | 89 | 2024-07-29 | 2026-07-17 |
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
bimekizumab, ustekinumab, placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Active not recruiting | 176 | 2024-06-25 | 2026-09-18 |
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
JNJ-77242113 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Active not recruiting | 19 | 2024-02-09 | 2026-09-28 |
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Guselkumab, Golimumab - Psoriatic Arthritis | Phase 3 | Active not recruiting | 63 | 2023-07-14 | 2026-11-05 |
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
TILD sub-cutaneous (SC) injection - Psoriatic Arthritis | Phase 3 | Active not recruiting | 529 | 2022-06-30 | 2026-03-05 |
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Ustekinumab - Crohn Disease, Colitis, Ulcerative | Phase 3 | Active not recruiting | 159 | 2021-10-18 | 2026-11-03 |
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
SHR0302 tablets、Placebo, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | 418 | 2021-08-30 | 2026-08-28 |
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Risankizumab - Psoriasis | Phase 3 | Active not recruiting | 132 | 2021-07-24 | 2025-08-12 |
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Deucravacitinib, Placebo, Apremilast - Psoriatic Arthritis | Phase 3 | Active not recruiting | 729 | 2021-07-15 | 2026-09-11 |
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Deucravacitinib, Placebo - Psoriatic Arthritis | Phase 3 | Active not recruiting | 670 | 2021-07-13 | 2026-10-16 |
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Guselkumab, Placebo - Arthritis, Psoriatic | Phase 3 | Active not recruiting | 1054 | 2021-06-17 | 2026-11-04 |
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Placebo, Risankizumab - Psoriatic Arthritis | Phase 3 | Active not recruiting | 964 | 2019-03-25 | 2025-08-05 |
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Placebo, Risankizumab - Psoriatic Arthritis (PsA) | Phase 3 | Active not recruiting | 444 | 2019-03-07 | 2026-10-28 |
Showing 20 of 21. Sign in to see all of them.
Narrower conditions
Arthritis, Psoriatic (16) · Colitis, Ulcerative (1) · Crohn Disease (1) · Joint Diseases (1)
Broader conditions
Skin Diseases (21) · Skin Diseases, Papulosquamous (21) · Skin and Connective Tissue Diseases (21) · Arthritis (16) · Bone Diseases (16) · Musculoskeletal Diseases (16) · Spinal Diseases (16) · Spondylarthritis (16) · Spondylarthropathies (16) · Spondylitis (16) · Joint Diseases (15) · Colitis (1) · Colonic Diseases (1) · Digestive System Diseases (1)
Interventions
risankizumab (4) · guselkumab (3) · Ustekinumab (2) · bimekizumab (2) · deucravacitinib (2) · sonelokimab (2) · Etanercept (1) · Injections (1) · apremilast (1) · golimumab (1)
Sponsors
Janssen Research & Development, LLC (5) · AbbVie (3) · Bristol-Myers Squibb (2) · MoonLake Immunotherapeutics AG (2) · UCB Biopharma SRL (2) · Alumis Inc (1) · Janssen Pharmaceutical K.K. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Sun Pharmaceutical Industries Limited (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · Takeda (1) · University of Pennsylvania (1)
Countries
United States (18) · Poland (17) · Germany (16) · Spain (15) · Canada (13) · Hungary (12) · Australia (11) · Czechia (11) · Italy (10) · Japan (10) · United Kingdom (9) · Argentina (8) · Bulgaria (8) · China (8) · France (7)
Top investigators
Alexis Ogdie-Beatty, MD, MSCE (1)
Results publications
PMID 36178584, PMID 38739215, PMID 39120849, PMID 41028616, PMID 41318485, PMID 34815219, PMID 34911706, PMID 35701011, PMID 35801915, PMID 36282530, PMID 36282537, PMID 36627711, PMID 38498139, PMID 38498141, PMID 39708367, PMID 40102973, PMID 41152645
NIH funding
2023 (7), 2017 (1)